Subcutaneous rotenone rat model of Parkinson's disease: Dose exploration study

详细信息    查看全文

• 作者：Zhen-Nian Zhang¹ ; Jing-Si Zhang¹ ; Jun Xiang ; Zhong-Hai Yu ; Wen Zhang ; Min Cai ; Xiang-Ting Li ; Ting Wu ; Wen-Wei Li ; Ding-Fang Cai ; ^{dingfangcai@163.com}
• 关键词：5-HT ; 5-hydroxytryptamine ; serotonin ; 6-OHDA ; 6-hydroxydopamine ; DA ; dopamine ; DOPAC ; dihydroxyphenylacetic acid ; EDTA ; ethylenediaminetetraacetic acid ; HPLC ; high performance liquid chromatography ; HVA ; homovanillic acid ; MPTP ; 1-methyl-4-phenyl-1 ; 2 ; 3 ; 6-tetrahydropyridine ; PBS ; phosphate-buffered saline ; PD ; Parkinson's disease ; SNc ; substantia nigra pars compacta ; TH ; tyrosine hydroxylase ; MAO-B ; monoamine oxidase-B
• 刊名：Brain Research
• 出版年：2017
• 出版时间：15 January 2017
• 年：2017
• 卷：1655
• 期：Complete
• 页码：104-113
• 全文大小：2863 K
• 卷排序：1655

文摘

We explored the effects of daily subcutaneous rotenone injections (1.5–2.5 mg/kg). Ultrastructural changes were observed in the substantia nigra at all doses. A dose-dependent increase in α-synuclein was also observed. 2 mg/kg/day rotenone reproduces behavior and neuropathology of parkinsonism. The low mortality rate at 2 mg/kg/day allows for practical application.